Skip to Sidebar Skip to Content

Cell and Gene Therapy Catapult

Innovate UK-backed advanced therapies catapult now making seed investments; first deal was Spliceor

  • Government & grants
  • London
Type
Government & grants
Based in
London
Stages
Pre-seed, Seed
Sector focus
Biotech & Life Sciences, Healthtech
Fund size
Undisclosed
Founded
2012

The Cell and Gene Therapy Catapult is a not-for-profit innovation centre established in 2012 within the Innovate UK Catapult Network to grow the UK's advanced therapies industry. Headquartered in London, it provides research, manufacturing and commercialisation support for cell and gene therapy developers. Under the Innovate UK-supported Cross-Catapult Investment Pilot it now makes seed investments in early-stage advanced therapy companies, assessed by a dedicated investment committee of therapy and venture specialists. Its first investment under the pilot, in 2025, went to Spliceor, a University of Cambridge spin-out developing a trans-splicing gene therapy platform with an initial focus on liver cancer.

Team

  • Matthew Durdy, Chief Executive
  • Jim Faulkner, Chairman

Portfolio in the directory

Add this profile to your website

Show this card on your own site. It reads “As seen on EP+” and links back to this page.

Paste it anywhere your site accepts HTML. Is this your organisation? Request an update if the card is out of date.

← All investors · Is this your organisation? Request an update

More investors in the directory

Subscribe to Newsletter

UK startup news, founder stories and funding insight, straight to your inbox every week. Free.